medigraphic.com
ISSN 0016-3813 (Print)

2016, Number 3

<< Back Next >>

Gac Med Mex 2016; 152 (3)

Prevalence of neuropsychiatric disorders in drug-naive subjects with Parkinson’s disease (PD)

Isais-Millán S, Piña-Fuentes D, Guzmán-Astorga C, Cervantes-Arriaga A, Rodríguez-Violante M

Language: Spanish
References: 30
Page: 357-363
PDF size: 87.45 Kb.


ABSTRACT

Introduction: Parkinson’s disease is characterized by a broad spectrum of neuropsychiatric manifestations. Its pathophysiology has been associated with the disease itself as well as with the dopaminergic treatment. Material and Methods: A cross-sectional study was conducted in drug-naive patients with early Parkinson’s disease. All participants were evaluated through a set of scales for specific neuropsychiatric symptoms including: cognition, depression, anxiety, apathy, psychosis, and impulse control disorder. Results: A total of 63 patients with Parkinson were included, of whom 26 (41.3%) subjects had some degree of cognitive impairment; seven (11.1%) had depression and 11 (15.8%) subjects had anxiety. Regarding the other symptoms, a total of 12 (19%) patients showed apathy, seven (11.1%) had psychosis, and eight (12.6%) patients had symptoms related to impulse control disorders. Conclusion: Neuropsychiatric disorders are common in drug-naive patients with early Parkinson’s disease. Given the impact of these symptoms on quality of life, identification and proper treatment is essential.


REFERENCES

  1. Poewe WH, Wenning GK. The natural history of Parkinson’s disease. Ann Neurol. 1998;44:S1-9.

  2. Glosser G, Clark C, Freundlich B, Kliner-Krenzel L, Flaherty P, Stern M. A controlled investigation of current and premorbid personality: characteristics of Parkinson’s disease patients. Mov Disord. 1995;10:201-6.

  3. Aarsland D, Larsen JP, Lim NG, et al. Range of neuropsychiatric disturbances in patients with Parkinson’s disease. J Neurol Neurosurg Psychiatry. 1999;67:492-6.

  4. Sung VW, Nicholas AP. Nonmotor symptoms in Parkinson’s disease: expanding the view of Parkinson’s disease beyond a pure motor, pure dopaminergic problem. Neurol Clin. 2013;31:S1-16.

  5. Faulkner MA. Safety overview of FDA-approved medications for the treatment of the motor symptoms of Parkinson’s disease. Expert Opin Drug Saf. 2014;13:1055-69.

  6. Gibb WR, Lees AJ. The relevance of the lewy body to the pathogenesis of idiopathic parkinson’s disease. J Neurol Neurosurg Psychiatry. 1988; 51:745-52.

  7. Goetz CG, Tilley BC, Shaftman SR, et al. Movement Disorder Societysponsored revision of the Unified Parkinson’s Disease Rating Scale (MDS‐UPDRS): Scale presentation and clinimetric testing results. Mov Disord. 2008;23(15):2129-70.

  8. Goetz CG, Poewe W, Rascol O, et al. Movement Disorder Society Task Force report on the Hoehn and Yahr staging scale: status and recommendations. Mov Disord. 2004;19:1020-8.

  9. Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N. The Parkinson’s Disease Questionnaire (PDQ-39): development and validation of a Parkinson’s disease summary index score. Age Ageing. 1997;26:353-7.

  10. Kandiah N, Zhang A, Cenina AR, Au WL, Nadkarni N, Tan LC. Montreal Cognitive Assessment for the screening and prediction of cognitive decline in early Parkinson’s disease. Parkinsonism Relat Disord. 2014; 20:1145-8.

  11. Leucht S, Kane JM, Kissling W, Hamann J, Etschel E, Engel R. Clinical implications of brief psychiatric rating scale scores. Br J Psychiatry. 2005;187:366-71.

  12. Llanero-Luque M, Ruiz-Sánchez de León JM, Pedrero-Pérez EJ, et al. Sintomatología disejecutiva en adictos a sustancias en tratamiento mediante la versión española del cuestionario disejecutivo (DEX-Sp). Rev Neurol. 2008;47:457-63.

  13. Zigmond AS, Snaith RP. The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand. 1983;67:361-70.

  14. Sockeel P, Dujardin K, Devos D, Deneve C, Destée A, Defebvre L. The Lille apathy rating scale (LARS), a new instrument for detecting and quantifying apathy: validation in Parkinson’s disease. J Neurol Neurosurg Psychiatry. 2006;77:579-84.

  15. Weintraub D, Mamikonyan E, Papay K, Shea JA, Xie SX, Siderowf A. Questionnaire for impulsive‐compulsive disorders in Parkinson’s Disease– Rating Scale. Mov Disord. 2012;27:242-7.

  16. Hilker R, Thomas AV, Klein JC, et al. Dementia in Parkinson disease: functional imaging of cholinergic and dopaminergic pathways. Neurology. 2005;65:1716-22.

  17. Meyer PT, Frings L, Hellwig S. Update on SPECT and PET in parkinsonism - part 2: biomarker imaging of cognitive impairment in Lewy-body diseases. Curr Opin Neurol. 2014;27:398-404.

  18. Garcia-Diaz AI, Segura B, Baggio HC, et al. Structural MRI correlates of the MMSE and pentagon copying test in Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:1405-10.

  19. Litvan I, Aarsland D, Adler CH, et al. MDS Task Force on mild cognitive impairment in Parkinson’s disease: critical review of PD-MCI. Mov Disord. 2011;26:1814-24.

  20. Weintraub D, Simuni T, Caspell-Garcia C, et al. Cognitive Performance and Neuropsychiatric Symptoms in Early, Untreated Parkinson’s Disease. Mov Disord. 2015;30:919-27.

  21. Nazem S, Siderworf AD, Duda J, et al. Montreal Cognitive Assessment performance in patients with Parkinson’s disease with “normal” global cognition according to Mini-Mental State Examination score. J Am Geriatrics Soc. 2009;57:304-8.

  22. Ceravolo R, Pagni C, Tognoni G, Bonuccelli U. The epidemiology and clinical manifestations of dysexecutive syndrome in Parkinson’s disease. Front Neurol. 2012;3:159.

  23. Gama RL, de Bruin VM, de Bruin PF, et al. Risk factors for visual hallucinations in patients with Parkinson’s disease. Neurol Res. 2015;37:112-6.

  24. Papapetropoulos S, Katzen H, Shrag A, et al. A questionnaire-based (UM-PDHQ) study of hallucinations in Parkinson’s disease. BMC Neurol. 2008;8:21.

  25. Sagna A, Gallo JJ, Pontone GM. Systematic review of factors associated with depression and anxiety disorders among older adults with Parkinson’s disease. Parkinsonism Relat Disord. 2014;20:708-15.

  26. Dujardin K, Langlois C, Plomhause L, et al. Apathy in untreated early- stage Parkinson disease: relationship with other non-motor symptoms. Mov Disord. 2014;29:1796-801.

  27. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson’s disease. J Nucl Med. 2005;46:227-32.

  28. Zhang G, Zhang Z, Liu L, et al. Impulsive and compulsive behaviors in Parkinson’s disease. Front Aging Neurosci. 2014;6:318.

  29. Giovannoni G, O’Sullivan J, Turner K, Manson A, Lees A. Hedonistic homeostatic dysregulation in patients with Parkinson’s disease on dopamine replacement therapies. J Neurol Neurosurg Psychiatry. 2000;68: 423-8.

  30. Grover S, Somaiya M, Kumar S, Avasthi A. Psychiatric aspects of Parkinson’s disease. J Neurosci Rural Pract. 2015;6:65-76.




2020     |     www.medigraphic.com